Poseida Therapeutics Stock News

Poseida Therapeutics, Inc. (NASDAQ:PSTX) Director Life Sciences Holdings L. Malin bought 71,312 shares of the stock in a transaction on Thursday, November 18th. The shares were bought at an average price of $7.18 per share, for a total transaction of $512,020.16. The purchase was disclosed in a document filed with the SEC, which is available []

Poseida Therapeutics, Inc. (NASDAQ:PSTX) Director Life Sciences Holdings L. Malin purchased 71,312 shares of the companys stock in a transaction that occurred on Thursday, November 18th. The shares were purchased at an average price of $7.18 per share, for a total transaction of $512,020.16. The transaction was disclosed in a filing with the SEC, which []

Boothbay Fund Management LLC bought a new position in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 13,304 shares of the companys stock, valued at approximately $133,000. Several other large investors have also added to or reduced their stakes in PSTX. Geode Capital Management LLC lifted its []

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create

The mean of analysts' price targets for Poseida Therapeutics, Inc. (PSTX) points to a 281% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem

Poseida Therapeutics: Genome Engineering For Safer Cell Therapies

Shares of Poseida Therapeutics Inc. PSTX, +1.22% were up 9.6% in premarket trading on Tuesday after the company said it signed a research and licensing agreement with Takeda Pharmaceutical Co. Ltd. 45

The death of a patient in a solid tumor trial hit Poseida Therapeutics Inc (NASDAQ: PSTX) hard last August, but since then, the hold has been lifted, and it is now reporting some early data from tha

SAN DIEGO, Aug. 31, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to creat

The FDA has cleared Poseida Therapeutics Inc (NASDAQ: PSTX) Investigational New Drug (IND) application for P-BCMA-ALLO1, a fully allogeneic CAR-T product candidate for relapsed/refractory multiple

SAN DIEGO, Aug. 30, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create

CDLX, UUUU, IVC, PSTX, and CYTK have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2021

SAN DIEGO, June 2, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create

SAN DIEGO, May 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create